This study evaluated the efficacy and safety of the combination of PD-1 and CTLA-4 inhibitors for patients with advanced ESCC, aiming to provide some enlightenment for advanced ESCC treatment. Here, CTLA4 is linked to esophageal squamous cell carcinoma.